SAN

80.9

-0.21%↓

UCB

240.9

-2.71%↓

SHL.DE

36.86

-3.38%↓

ARGX

677

-1.34%↓

VIE

35.26

-0.11%↓

SAN

80.9

-0.21%↓

UCB

240.9

-2.71%↓

SHL.DE

36.86

-3.38%↓

ARGX

677

-1.34%↓

VIE

35.26

-0.11%↓

SAN

80.9

-0.21%↓

UCB

240.9

-2.71%↓

SHL.DE

36.86

-3.38%↓

ARGX

677

-1.34%↓

VIE

35.26

-0.11%↓

SAN

80.9

-0.21%↓

UCB

240.9

-2.71%↓

SHL.DE

36.86

-3.38%↓

ARGX

677

-1.34%↓

VIE

35.26

-0.11%↓

SAN

80.9

-0.21%↓

UCB

240.9

-2.71%↓

SHL.DE

36.86

-3.38%↓

ARGX

677

-1.34%↓

VIE

35.26

-0.11%↓

Search

Laboratorios Farmaceuticos Rovi SA

Fechado

SetorSaúde

85.55 0.06

Visão Geral

Variação de preço das ações

24h

Atual

Mín

84.35

Máximo

86.2

Indicadores-chave

By Trading Economics

Rendimento

-33M

43M

Vendas

7.9M

218M

P/E

Médio do Setor

36.483

60.328

EPS

0.834

Margem de lucro

19.539

Funcionários

1,950

EBITDA

-21M

63M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+1.4% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

427M

4.4B

Abertura anterior

85.49

Fecho anterior

85.55

Sentimento de Notícias

By Acuity

50%

50%

163 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

21 de abr. de 2026, 23:27 UTC

Notícias Principais

BHP Expects Annual Copper Output in Upper Half of Guidance, Finishes China Iron-Ore Negotiations

21 de abr. de 2026, 23:27 UTC

Ações em Alta

Stocks to Watch: Sonoco Products, Adobe, Manhattan Associates, Target Hospitality

21 de abr. de 2026, 23:02 UTC

Ganhos

Correction to Capital One Financial 1Q Earnings Article

21 de abr. de 2026, 23:47 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 de abr. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Decline as Hopes for U.S.-Iran Peace Talks Fade -- Market Talk

21 de abr. de 2026, 23:36 UTC

Conversa de Mercado
Notícias Principais

Market Talk Roundup: Latest on U.S. Politics

21 de abr. de 2026, 23:36 UTC

Conversa de Mercado
Notícias Principais

Gold Edges Higher After Trump Says U.S. Will Extend Cease-Fire Deadline -- Market Talk

21 de abr. de 2026, 23:32 UTC

Ganhos

America Movil 1Q EBITDA MXN94.5B, Up 3.8% on Year >AMX

21 de abr. de 2026, 23:30 UTC

Ganhos

America Movil 1Q Rev MXN236.84B, Up 2.1% on Year >AMX

21 de abr. de 2026, 23:28 UTC

Ganhos

America Movil 1Q Net MXN23.4B Vs. Net MXN18.7B >AMX

21 de abr. de 2026, 23:16 UTC

Notícias Principais

Ampol Entered 2Q With Hedge Book Positioned to Mitigate Volatility

21 de abr. de 2026, 23:15 UTC

Notícias Principais

Ampol Entered 2Q With Broad-Based Momentum

21 de abr. de 2026, 23:15 UTC

Notícias Principais

Ampol: Suitable Crudes for Lytton Remain Available in Market

21 de abr. de 2026, 23:14 UTC

Notícias Principais

Ampol: Crude Supplies Secured Into July

21 de abr. de 2026, 23:14 UTC

Notícias Principais

Ampol: Fuel Supplies Secured Until at Least End of May

21 de abr. de 2026, 23:13 UTC

Notícias Principais

Ampol: Well Placed for Crude, Product Supply Prior to Iran Conflict

21 de abr. de 2026, 23:13 UTC

Notícias Principais

Ampol 1Q Lytton Refinery Production 1.43 Billion Liters

21 de abr. de 2026, 23:12 UTC

Notícias Principais

Ampol 1Q Lytton Refiner Margin US$25.45/Bbl

21 de abr. de 2026, 22:54 UTC

Conversa de Mercado

Sell America Trade Could Gain Momentum If Fed Uncertainty Unresolved -- Market Talk

21 de abr. de 2026, 22:49 UTC

Notícias Principais

BHP 3Q Average Realized Energy Coal Price $105.61/Ton, Up 10% On-Quarter

21 de abr. de 2026, 22:49 UTC

Notícias Principais

BHP 3Q Average Realized Steelmaking Coal Price $226.76/Ton, Up 15% On-Quarter

21 de abr. de 2026, 22:48 UTC

Notícias Principais

BHP 3Q Average Realized Iron Ore Price $85.35/Ton, Flat On-Quarter

21 de abr. de 2026, 22:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Alliance Portfolio Is Comprised of Five Plants: Batavia, Hillburn, Massena, Shoemaker and Sterling

21 de abr. de 2026, 22:48 UTC

Notícias Principais

BHP 3Q Average Realized Copper Price $5.86/Pound, Down 1% On-Quarter

21 de abr. de 2026, 22:48 UTC

Aquisições, Fusões, Aquisições de Empresas

PowerTransitions to Buy 323 MW of Power Generation Assets in New York State From Alliance Energy Group

21 de abr. de 2026, 22:46 UTC

Notícias Principais

BHP: Has Concluded Iron Ore Sales Contract Negotiations With China Mineral Resources Group

21 de abr. de 2026, 22:45 UTC

Notícias Principais

BHP: Pampa Norte Production Down on Ore Complexity, Variation; Declining Grades

21 de abr. de 2026, 22:45 UTC

Notícias Principais

BHP: Escondida Concentrator Investment Estimated Between $4.4 Billion-$5.9 Billion

21 de abr. de 2026, 22:44 UTC

Notícias Principais

BHP: Escondida Concentrator Project Seen Facing FID in 2027-28

21 de abr. de 2026, 22:42 UTC

Notícias Principais

BHP CEO: Centralized Procurement, Low-cost Operations Help Buffer Industry Wide Cost Pressures

Comparação entre Pares

Variação de preço

Laboratorios Farmaceuticos Rovi SA Previsão

Preço-alvo

By TipRanks

1.4% parte superior

Previsão para 12 meses

Média 86.75 EUR  1.4%

Máximo 90 EUR

Mínimo 83.5 EUR

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Laboratorios Farmaceuticos Rovi SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

1

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

51.1 / N/ASuporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

163 / 348 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat